Labcorp (NYSE:LH) Upgraded to "Strong-Buy" at Wall Street Zen

Labcorp logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Labcorp to “Strong Buy.” Analysts overall remain moderately positive, with a consensus “Moderate Buy” rating and an average price target of $369.08.
  • Labcorp beat quarterly expectations, reporting adjusted earnings of $4.78 per share versus $4.64 expected and revenue of $3.81 billion versus $3.76 billion. Revenue rose 6.9% year over year.
  • Shares opened at $367.12, near the company’s 12-month high of $375.10. Insiders sold 3,749 shares worth about $1.38 million over the past three months.
  • MarketBeat previews the top five stocks to own by December 1st.

Labcorp (NYSE:LH - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research firms have also weighed in on LH. Robert W. Baird lifted their price objective on shares of Labcorp from $361.00 to $396.00 and gave the company an "outperform" rating in a research report on Thursday, October 29th. JPMorgan Chase & Co. lifted their price objective on Labcorp from $330.00 to $360.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Leerink Partners set a $410.00 price target on shares of Labcorp in a report on Wednesday, October 28th. Truist Financial increased their price objective on Labcorp from $365.00 to $395.00 and gave the company a "buy" rating in a research note on Thursday, October 29th. Finally, HSBC upgraded shares of Labcorp from a "hold" rating to a "buy" rating and set a $410.00 target price on the stock in a research report on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $369.08.

Read Our Latest Analysis on Labcorp

Labcorp Stock Down 0.5%

Shares of LH opened at $367.12 on Friday. The company's 50-day moving average price is $334.72 and its 200 day moving average price is $295.06. The firm has a market cap of $29.81 billion, a P/E ratio of 20.59, a price-to-earnings-growth ratio of 2.10 and a beta of 0.86. Labcorp has a 12-month low of $245.00 and a 12-month high of $375.10. The company has a current ratio of 1.41, a quick ratio of 1.22 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 EPS for the quarter, topping the consensus estimate of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the business posted $4.18 earnings per share. The company's quarterly revenue was up 6.9% on a year-over-year basis. On average, sell-side analysts forecast that Labcorp will post 18.51 earnings per share for the current year.

Insider Activity

In other Labcorp news, EVP Amy B. Summy sold 365 shares of Labcorp stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $372.58, for a total transaction of $135,991.70. Following the sale, the executive vice president directly owned 6,590 shares in the company, valued at $2,455,302.20. The trade was a 5.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brian J. Caveney sold 2,000 shares of the firm's stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $372.04, for a total transaction of $744,080.00. Following the transaction, the executive vice president directly owned 34,562 shares of the company's stock, valued at approximately $12,858,446.48. This represents a 5.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,749 shares of company stock worth $1,377,699 over the last three months. Insiders own 0.84% of the company's stock.

Institutional Investors Weigh In On Labcorp

A number of institutional investors have recently made changes to their positions in the company. Carolina Financial Advisors Inc increased its stake in Labcorp by 2.1% during the third quarter. Carolina Financial Advisors Inc now owns 1,374 shares of the medical research company's stock valued at $423,000 after purchasing an additional 28 shares during the last quarter. Kestra Advisory Services LLC boosted its position in Labcorp by 6.3% during the 3rd quarter. Kestra Advisory Services LLC now owns 6,253 shares of the medical research company's stock worth $1,927,000 after acquiring an additional 373 shares during the period. Advisors Asset Management Inc. bought a new position in Labcorp in the 3rd quarter valued at about $1,840,000. Innovator Capital Management LLC bought a new position in shares of Labcorp in the third quarter valued at approximately $1,388,000. Finally, Zacks Investment Management boosted its stake in Labcorp by 4.2% during the 3rd quarter. Zacks Investment Management now owns 89,168 shares of the medical research company's stock valued at $27,474,000 after purchasing an additional 3,600 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors.

About Labcorp

(Get Free Report)

Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.

Featured Articles

Analyst Recommendations for Labcorp (NYSE:LH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Labcorp Right Now?

Before you consider Labcorp, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.

While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines